Innate Pharma Q2 Earnings Call Highlights

Innate Pharma S.A. reported on its Q2 earnings call, highlighting several key developments. The company strengthened its finances through a partnership with Sobi for lacutamab, securing a $75 million upfront payment and €30 million in equity financing, which is expected to extend its cash runway through the end of Q1 2028. Additionally, Innate Pharma initiated the TELLOMAK-3 confirmatory phase III trial for lacutamab, with the first patient expected to enroll in Q1 2027.

The trial aims to confirm the efficacy of lacutamab in Sézary syndrome and mycosis fungoides, with potential accelerated approval for Sézary syndrome in the second half of 2027.

Brief written by urgent.news from Yahoo Finance's own syndicated text. Machine-written — may contain errors; check the original before relying on it.